Compare Amgen, Inc. (AMGN) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ThredUp Inc — how do they compare? Amgen, Inc. trades at $356.73 (market cap $196.12B), while ThredUp Inc trades at $6.15 (market cap $850.38M). The key difference: Amgen, Inc. is far larger — about 230.6× ThredUp Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| AMGN | TDUP | |
|---|---|---|
Market Cap | $196.12B | $850.38M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $12.08 |
52-Week Low | $271.18 | $3.11 |
Enterprise Value | $241.41B | $853.11M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ThredUp (TDUP) trades at $6.60, up 0.38% on the day, with a bullish technical signal and strong analyst support (57% buy ratings). The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, and a gross margin of 79.2%, though net losses persist. Recent initiatives include launching a peer-to-peer marketplace and AI-driven shopping tools to boost growth.
The outlook is cautiously optimistic, with a consensus price target of $6.90 offering modest upside. Key opportunities lie in margin improvement and AI efficiency gains, but risks include sustained profitability challenges and competitive pressures in online resale. Investors should weigh growth potential against ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
